1. Home
  2. KRYS vs ICLR Comparison

KRYS vs ICLR Comparison

Compare KRYS & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krystal Biotech Inc.

KRYS

Krystal Biotech Inc.

HOLD

Current Price

$298.90

Market Cap

7.8B

Sector

Health Care

ML Signal

HOLD

Logo ICON plc

ICLR

ICON plc

HOLD

Current Price

$116.01

Market Cap

9.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRYS
ICLR
Founded
2015
1990
Country
United States
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8B
9.3B
IPO Year
2017
2001

Fundamental Metrics

Financial Performance
Metric
KRYS
ICLR
Price
$298.90
$116.01
Analyst Decision
Strong Buy
Buy
Analyst Count
11
13
Target Price
$297.60
$178.62
AVG Volume (30 Days)
273.5K
1.3M
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
128.00
N/A
EPS
1.83
N/A
Revenue
$389,130,000.00
N/A
Revenue This Year
$38.74
N/A
Revenue Next Year
$32.53
N/A
P/E Ratio
$166.58
$12.91
Revenue Growth
33.94
N/A
52 Week Low
$123.03
$66.57
52 Week High
$319.48
$211.00

Technical Indicators

Market Signals
Indicator
KRYS
ICLR
Relative Strength Index (RSI) 55.98 50.50
Support Level $253.89 $99.11
Resistance Level $319.48 $121.03
Average True Range (ATR) 11.79 6.15
MACD -0.87 -0.64
Stochastic Oscillator 46.86 32.51

Price Performance

Historical Comparison
KRYS
ICLR

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About ICLR ICON plc

Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.

Share on Social Networks: